CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Cadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant Epilepsy

RegulatoryapprovedBiomarker Targeted Stimulation Therapy (BTSEE study)Positive
AI Analysis

Summary

Cadence Neuroscience received FDA IDE approval to begin a prospective multicenter study (BTSEE) of its biomarker-targeted stimulation therapy in 45 pediatric and adult patients with focal drug-resistant epilepsy at up to 10 U.S. comprehensive epilepsy centers.

Clinical Trial Data

Patients

45

Outcome Details

FDA approved Investigational Device Exemption (IDE) enabling a prospective multicenter BTSEE study in 45 pediatric and adult patients at up to 10 U.S. comprehensive epilepsy centers.

Importance:5/10
Sentiment:
0.50
FDAIDE approvalepilepsyneuromodulationmedical devicedrug-resistant epilepsypediatricclinical trial start
Related Companies
$CMHSF$GTHP

Read the original article

Published by PR Newswire Biotech on October 14, 2026 1:00 PM

Read Original